The European Patent Office (EPO) has published a new patent application, EP4626881A1, detailing fused azole derivatives designed as diacylglyceride O-acyltransferase 2 (DGAT2) inhibitors. The applicant, Merck Sharp & Dohme LLC, claims these compounds are novel and may be useful in treating conditions related to DGAT2 activity, such as obesity, diabetes, and cardiovascular diseases. The application includes specific chemical structures and classifications (IPC: C07D) and lists designated states across Europe where patent protection is sought.

This publication represents the grant of a patent application, not a regulatory rule imposing obligations. However, it signifies the EPO's recognition of potential intellectual property in this area of pharmaceutical research. Companies involved in drug development, particularly those targeting metabolic pathways or cardiovascular health, should be aware of this patent as it may affect their own research and development activities or potential licensing opportunities. No immediate compliance actions are required for entities outside of Merck Sharp & Dohme LLC, but it highlights a specific area of innovation in pharmaceutical chemistry.